Literature DB >> 6439269

Triggering by Paf-acether and adrenaline of cyclo-oxygenase-independent platelet aggregation.

F Fouque, B B Vargaftig.   

Abstract

Platelet-activating factor (Paf-acether, 1-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine) induced full aggregation and a limited release reaction of human platelets in plasma or in blood. Cyclo-oxygenase inhibition with aspirin only reduced aggregation when induced by threshold amounts of Paf-acether, whereas higher concentrations surmounted inhibition whether tested in citrated or in heparinized platelet-rich plasma or blood. Aspirin-induced inhibition of platelet secretion by Paf-acether was insurmountable and independent of the anti-coagulant used. Paf-acether and adrenaline acted synergistically in inducing aggregation in citrate and heparin. Aspirin in vitro or after oral ingestion at doses that suppressed aggregation induced by arachidonic acid alone, failed to reduce significantly the synergized aggregation induced by Paf-acether alone or combined with adrenaline. Twenty-four hours after the oral ingestion of aspirin, when aggregation by arachidonic acid remained blocked, a slight inhibitory activity on the effect of Paf-acether noted 4 h after aspirin, had ceased. This was probably accounted for by the synthesis of thromboxane A2 by newly formed platelets, since the in vitro addition of aspirin, or of the thromboxane/endoperoxide receptor inhibitor 13-azaprostanoic acid caused the 24 h platelets to behave in a manner similar to platelets collected 4 h after aspirin. The alpha 2-adrenoceptor inhibitor, yohimbine, blocked the direct effect of adrenaline as well as its synergism with Paf-acether. Since the synergistic effect of Paf-acether and adrenaline was maintained when thrombin-degranulated platelets were used, and aspirin remained ineffective against it, it is clear that the augmented platelet responsiveness is not accounted for by the platelet release reaction. 6 Paf-acether and adrenaline act synergistically and stimulate platelets by cyclo-oxygenaseindependent mechanisms, which may be relevant in human physiopathological conditions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6439269      PMCID: PMC1987093          DOI: 10.1111/j.1476-5381.1984.tb16216.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  Aggregation of rabbit platelets by platelet-activating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane-active drugs.

Authors:  J P Cazenave; J Benveniste; J F Mustard
Journal:  Lab Invest       Date:  1979-09       Impact factor: 5.662

2.  Studies on the mechanism of platelet aggregation and release reaction induced by collagen and adrenaline.

Authors:  S Bygdeman; O Tangen
Journal:  Thromb Res       Date:  1977-08       Impact factor: 3.944

3.  The role of platelet-activating factor in platelet aggregation.

Authors:  M Chignard; J P Le Couedic; M Tence; B B Vargaftig; J Benveniste
Journal:  Nature       Date:  1979-06-28       Impact factor: 49.962

4.  Platelet aggregation induced by arachidonic acid is accompanied by release of potential inflammatory mediators distinct from PGE2 and PGF2.

Authors:  B B Vargaftig; P Zirinis
Journal:  Nat New Biol       Date:  1973-07-25

5.  Effects of heparin on platelet reactivity in citrated plasma.

Authors:  E A Beck
Journal:  Thromb Haemost       Date:  1977-08-31       Impact factor: 5.249

6.  The effects of alpha adrenergic agents on human platelet aggregation.

Authors:  C Y Hsu; D R Knapp; P V Halushka
Journal:  J Pharmacol Exp Ther       Date:  1979-03       Impact factor: 4.030

7.  Properties of washed human platelets.

Authors:  R L Kinlough-Rathbone; J F Mustard; M A Packham; D W Perry; H J Reimers; J P Cazenave
Journal:  Thromb Haemost       Date:  1977-04-30       Impact factor: 5.249

8.  13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor.

Authors:  G C Le Breton; D L Venton; S E Enke; P V Halushka
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

9.  In vitro and in vivo functions of thrombin-treated platelets.

Authors:  H J Reimers; R L Kinlough-Rathbone; J P Cazenave; A F Senyi; J Hirsh; M A Packham; J F Mustard
Journal:  Thromb Haemost       Date:  1976-02-29       Impact factor: 5.249

10.  Convulxin-induced activation of intact and of thrombin-degranulated rabbit platelets: specific crossed desensitisation with collagen.

Authors:  B B Vargaftig; D Joseph; F Wal; G Marlas; M Chignard; L G Chevance
Journal:  Eur J Pharmacol       Date:  1983-08-19       Impact factor: 4.432

View more
  14 in total

1.  Effects of aspirin, dipyridamole, nifedipine and cavinton which act on platelet aggregation induced by different aggregating agents alone and in combination.

Authors:  S E Akopov; E S Gabrielian
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Selective inhibition of adrenaline-induced human platelet aggregation by the structurally related Paf antagonist Ro 19-3704.

Authors:  M Schattner; A Parini; F Fouque; B B Vargaftig; L Touqui
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

3.  Proceedings of the British Pharmacological Society. 10th-18th September 1986. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1986-12       Impact factor: 8.739

4.  At low extracellular calcium concentration platelet activating factor induces beta-thromboglobulin release from human platelets through thromboxane-endoperoxides formation.

Authors:  A Zatta; A Zanetti; E Dejana; M Prosdocimi
Journal:  Agents Actions       Date:  1987-10

5.  Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations.

Authors:  R L Jones; H Wise; R Clark; R L Whiting; K R Bley
Journal:  Br J Pharmacol       Date:  2006-07-31       Impact factor: 8.739

6.  Paf. A mediator in search of a disease.

Authors:  B B Vargaftig
Journal:  Clin Rev Allergy       Date:  1994

7.  Antagonists of PAF-acether do not suppress thrombin-induced aggregation of ADP-deprived and aspirin-treated human platelets.

Authors:  S Adnot; D Joseph; B B Vargaftig
Journal:  Agents Actions       Date:  1987-06

8.  The effects of varying doses of aspirin on human platelet activation induced by PAF, collagen and arachidonic acid.

Authors:  M L Taylor; N L Misso; G A Stewart; P J Thompson
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

9.  Possible mechanisms of the potentiation of blood-platelet activation by adrenaline.

Authors:  M Bushfield; A McNicol; D E MacIntyre
Journal:  Biochem J       Date:  1987-02-01       Impact factor: 3.857

10.  Interaction of a new low molecular weight heparin (OP/LMWH) with human platelets.

Authors:  R Mastacchi; M Barbanti; P Bianchini; B Osima
Journal:  Agents Actions       Date:  1986-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.